02/29/2024, 2049 characters
The US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) has determined to recommend Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of chikungunya virus disease. Juan Carlos Jaramillo, Chief Medical Officer of Valneva commented: “Chikungunya poses a significant risk to individuals traveling to or living in regions where the chikungunya virus and the mosquitoes that transmit it are common. IXCHIQ® offers benefits for travelers, for those on vacation or visiting family, as well as for people conducting business, missions, or laboratory work. We welcome the ACIP recommendation identifying IXCHIQ® as the only approved and recommended vaccine for the target population. We will “We will continue to work with regulatory authorities worldwide to enable access to IXCHIQ® in all regions.”
The ACIP recommendations will be forwarded to the Director of the CDC and the U.S. Department of Health and Human Services for review and approval. Once approved, final recommendations will be published in a future Morbidity and Mortality Weekly Report (MMWR) to inform healthcare providers on appropriate use of the vaccine.
ACIP recommends IXCHIQ® for individuals ≥18 years of age traveling to a country or area experiencing a chikungunya outbreak. In addition, it may be considered for individuals traveling to a country or area without an outbreak but with evidence of CHIKV transmission within the last five years and who are >65 years of age and are expected to have at least moderate exposure to mosquitoes (at least two weeks, cumulative), or who are traveling for a longer period of time (six months or more, cumulative). The ACIP also recommends chikungunya vaccination for laboratory workers who may be exposed to the chikungunya virus.
BSN Podcasts
Christian Drastil: Vienna Stock Exchange chat
Vienna Stock Exchange Party #598: Relaunch the Vienna financial market? Do&Co is back at an all-time high, being a general contractor is good
Photo credit
1. Valneva, laboratory, vaccine, Credit: Valneva , (© Sender) >> Open on photaq.com
Stocks on the radar:Porr, Vienna Airport, UBM, Amag, Rosenbauer, Austriacard Holdings AG, Composite, Semperite, Bawag, EVN, Austrian post, AT&S, Strabag, Agrana, Real estate finance, Telekom Austria, Marinomed Biotech, Pierer Mobility, S Realty, RHI Magnesita, Addiko Bank, CA Realty, First Group, Uniqa, VIG, Wienerberger, Siemens Energy, BMW, Porsche Automobil Holding, DAIMLER TRUCK HLD…, HeidelbergCement.
Random partners
Strabag
Strabag SE is a European technology group for construction services. The offering covers all areas of the construction industry and covers the entire construction value chain. Thanks to the commitment of almost 72,000 employees, the company generates an annual output of around 14 billion euros (as of June 2017).
>> Visit 68 other partners at boerse-social.com/partner
Valneva, laboratory, vaccine, Credit: Valneva, (© issuer)
author
Christine Petzwinkler
Stock exchange social network/magazine